Reuters logo
BRIEF-GSK CEO expects successor to be named towards end of 2016
2016年4月27日 / 中午11点52分 / 1 年前

BRIEF-GSK CEO expects successor to be named towards end of 2016

April 27 (Reuters) - GlaxoSmithKline Chief Executive Andrew Witty told reporters:

* Ceo says expects naming of new ceo towards end of this year

* Ceo says making more rapid progress on consumer margins than initially planned

* Ceo says price for ada scid gene therapy will be significantly less expensive than for other such therapies

* Ceo says expects to grow respiratory business this year, driven by new products

* Ceo says earliest window for u.s. generic advair competition q2 2017

* Ceo says sees m&a as tactical opportunity but not central to strategy

* Ceo says brexit concerns not affecting staff recruitment

* Ceo says u.s. drug pricing pressure won’t ease after election Further company coverage: (Reporting by UK bureau)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below